Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer

British Journal of Cancer

Volumn 112, Issue 4, 2015, Pages 624-629

  Hansen, T F ^a,b   Carlsen, A L ^c   Heegaard, N H H ^c   Sorensen F B ^a,b   Jakobsen, A ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

angiogenesis; chemotherapy; colorectal cancer; microRNA 126; microvesicles; predictive markers

Indexed keywords

BEVACIZUMAB; CAPECITABINE; MICRORNA 126; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; MICRORNA; MIRN126 MICRORNA, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RNA PURIFICATION; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COLORECTAL NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84923598906     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.652     Document Type: Article

References (32)

1. Bakouboula B, Morel O, Faure A, Zobairi F, Jesel L, Trinh A, Zupan M, Canuet M, Grunebaum L, Brunette A, Desprez D, Chabot F, Weitzenblum E, Freyssinet JM, Chaouat A, Toti F. (2008). Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med 177: 536-543
2. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, ZhangH, Shang X, Gong T, Ning G,Wang J, Zen K, Zhang J, Zhang CY. (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006
3. Cocucci E, Racchetti G, Meldolesi J. (2009). Shedding microvesicles: artefacts no more. Trends Cell Biol 19: 43-51
4. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247
5. Esquela-Kerscher A, Slack FJ. (2006). Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269
6. Filipowicz W, Bhattacharyya SN, Sonenberg N. (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet 9: 102-114
7. Ferrara N, Gerber HP, LeCouter J. (2003). The biology of VEGF and its receptors. Nat Med 9: 669-676
8. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. (2008). miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15: 272-284
9. Hansen TF, Christensen Rd, Andersen RF, Sorensen FB, Johnsson A, Jakobsen A. (2013). MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer 109: 1243-1251
10. Hansen TF, Soerensen FB, Lindebjerg J, Jakobsen A. (2012). The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer 8: 83
11. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB. (2008). Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3: e3694
12. Jain RK. (2013). Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31: 2205-2218
13. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. (2012). microRNAs in cancer management. Lancet Oncol 13: 249-258
14. Kosaka N, Iguchi H, Ochiya T. (2010). Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101: 2087-2092
15. Lee Y, El AS, Wood MJ. (2012). Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 21: 125-134
16. Malka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, Pierga JY, Conroy T, Chauffert B, Francois E, Guichard P, Galais MP, Cvitkovic F, Ducreux M, Farace F. (2012). Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol 23: 919-927
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. (2005). Reporting recommendations for tumour marker prognostic studies (REMARK). Br J Cancer 93: 387-391
18. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova- Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518
19. Mocharla P, Briand S, Giannotti G, Dorries C, Jakob P, Paneni F, Luscher T, Landmesser U. (2013). AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. Blood 121: 226-236
20. Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield EA, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J. (2011). Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol 119: 92-101
21. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. (2009). Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58: 1375-1381
22. Palma J, Yaddanapudi SC, Pigati L, Havens MA, Jeong S, Weiner GA, Weimer KM, Stern B, Hastings ML, Duelli DM. (2012). MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res 40: 9125-9138
23. Schmittgen TD, Livak KJ. (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108
24. Tomasetti M, Staffolani S, Nocchi L, Neuzil J, Strafella E, Manzella N, Mariotti L, Bracci M, Valentino M, Amati M, Santarelli L. (2012). Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem 45: 575-581
25. Triozzi PL, Achberger S, Aldrich W, Singh AD, Grane R, Borden EC. (2012). The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. J Transl Med 10: 241
26. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659
27. Wang LG, Gu J. (2012). Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol 36: 61-67
28. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN. (2008). The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 15: 261-271
29. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. (2010). The microRNA spectrum in 12 body fluids. Clin Chem 56: 1733-1741
30. Wienholds E, Kloosterman WP, Miska E, varez-Saavedra E, Berezikov E, De BE, Horvitz HR, Kauppinen S, Plasterk RH. (2005). MicroRNA expression in zebrafish embryonic development. Science 309: 310-311
31. Willett CG, Duda DG, di TE, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. (2009). Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27: 3020-3026
32. Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu T, Bai Y, Shen Y, Yuan W, Jing Q, Qin Y. (2011). Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem 351: 157-164